BioCentury
ARTICLE | Company News

Novogen, Yale University deal

May 9, 2016 7:00 AM UTC

Novogen said it ceased funding and will wind down operations of its 2013 CanTx Inc. JV with the university as the biotech plans to move Cantrixil in to Phase I trials, which are expected to begin nex...